Lipids, Blood Pressure, Kidney-what was New in 2012?

Banach, Maciej; Hering, Dagmara; Myśliwiec, Michał; Rysz, Jacek; Małyszko, Jolanta

doi:10.3923/ijp.2012.659.678

Cited by 9 publications

(8 citation statements)

References 210 publications

(150 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Importantly, hypertension usually coexists with lipid disorders (even in >50 % of individuals over 55 years of age) [ 32 – 34 ] Thus, the link between hypertension and cognitive function can be affected by coexisting dyslipidaemia and its treatment with statins, which might increase the risk of cognitive impairments, especially in elderly patients ( http://www.fda.gov/drugs/drugsafety/ucm293101.htm ). While the above-mentioned evidence supporting the contribution of midlife hypertension to cognitive decline is growing, the impact of late-life BP is more controversial.…”

Section: Blood Pressure and The Risk Of Cognitive Declinementioning

confidence: 99%

Hypertension, Brain Damage and Cognitive Decline

et al. 2013

Self Cite

View full text Add to dashboard Cite

Loss of cognitive function is one the most devastating manifestations of ageing and vascular disease. Cognitive decline is rapidly becoming an important cause of disability worldwide and contributes significantly to increased mortality. There is growing evidence that hypertension is the most important modifiable vascular risk factor for development and progression of both cognitive decline and dementia. High blood pressure contributes to cerebral small and large vessel disease resulting in brain damage and dementia. A decline in cerebrovascular reserve capacity and emerging degenerative vascular wall changes underlie complete and incomplete brain infarcts, haemorrhages and white matter hyperintensities. This review discusses the complexity of factors linking hypertension to brain functional and structural changes, and to cognitive decline and dementia. The evidence for possible clinical markers useful for prevention of decreased cognitive ability, as well as recent data on vascular mechanism in the pathogenesis of cognitive decline, and the role of antihypertensive therapies in long-term prevention of late-life cognitive decline will be reviewed.

show abstract

Section: Blood Pressure and The Risk Of Cognitive Declinementioning

confidence: 99%

Hypertension, Brain Damage and Cognitive Decline

et al. 2013

Self Cite

View full text Add to dashboard Cite

show abstract

“…The heterogeneity of HDL particles in terms of shape, size and apolipoprotein composition was shown to determine their ability to inhibit LDL oxidation and reduce migration of monocytes within the arterial wall [ 18 , 19 ]. Dysfunctional HDL loses the function of reverse cholesterol transport and might exhibit pro-inflammatory, pro-oxidant, pro-thrombotic and pro-apoptotic properties, all responsible for the subsequent endothelial dysfunction [ 19 , 20 ].…”

Section: Lipid Update 2013mentioning

confidence: 99%

Lipid, blood pressure and kidney update 2013

et al. 2014

Self Cite

View full text Add to dashboard Cite

The year 2013 proved to be very exciting as far as landmark trials and new guidelines in the field of lipid disorders, blood pressure and kidney diseases. Among these are the International Atherosclerosis Society Global Recommendations for the Management of Dyslipidemia, European Society of Cardiology (ESC)/European Society of Hypertension Guidelines for the Management of Arterial Hypertension, American Diabetes Association Clinical Practice Recommendations, the Kidney Disease: Improving Global Outcomes Clinical Practice Guidelines for Managing Dyslipidemias in Chronic Kidney Disease (CKD) Patients, the American College of Cardiology/American Heart Association Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults, the Joint National Committee Expert Panel (JNC 8) Evidence-Based Guideline for the Management of High Blood Pressure in Adults, the American Society of Hypertension/International Society of Hypertension Clinical Practice Guidelines for the Management of Hypertension in the Community, the American College of Physicians Clinical Practice Guideline on Screening, Monitoring, and Treatment of Stage 1–3 CKD and many important trials presented among others during the ESC Annual Congress in Amsterdam and the American Society of Nephrology Annual Meeting—Kidney Week in Atlanta, GA. The paper is an attempt to summarize the most important events and reports in the mentioned areas in the passing year.

show abstract

“…Results of experimental studies confirmed that lipid abnormalities may contribute to the progression of kidney disease [38]. According to studies, in pre-dialysis CKD patients, statins reduce TCh, LDL-C and triglyceride levels depending on the duration of the treatment [42][43][44]. A study by Di Lullo et al [45] demonstrated that fluvastatin, which is safe and well tolerated in CKD patients, not only improves the lipid profile but also may contribute to nephroprotection.…”

Section: Effects Of Statins On Lipid Profilementioning

confidence: 81%

Should we use statins in all patients with chronic kidney disease without dialysis therapy? The current state of knowledge

et al. 2015

Self Cite

View full text Add to dashboard Cite

Meta-analyses results suggest that statins are associated with lipid lowering, cardiovascular and anti-proteinuric benefits in CKD patients. However, their effects on overall and cardiovascular mortality are much less obvious. Bearing in mind the advantageous effects and low risk of adverse effects, it seems that mild renal impairment should not exclude these patients from receiving a statin. However, because CKD patients in stages III-V are underrepresented in clinical trials, administration of statins to these patients who have not yet had a vascular event remains controversial.

show abstract

Lipids, Blood Pressure, Kidney-what was New in 2012?

Cited by 9 publications

References 210 publications

Hypertension, Brain Damage and Cognitive Decline

Hypertension, Brain Damage and Cognitive Decline

Lipid, blood pressure and kidney update 2013

Should we use statins in all patients with chronic kidney disease without dialysis therapy? The current state of knowledge

Contact Info

Product

Resources

About